Mineralys Therapeutics (MLYS) Depreciation & Amortization (CF) (2024 - 2026)

Mineralys Therapeutics has disclosed Depreciation & Amortization (CF) across 3 years of filings, most recently posting $6000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $6000.0, down 60.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $50000.0 (changed 0.0% YoY), and the FY2025 annual result was $59000.0, up 37.21% from the prior year.
• Depreciation & Amortization (CF) came in at $6000.0 for Q1 2026 at Mineralys Therapeutics, down from $13000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $16000.0 in Q2 2025 to a low of $6000.0 in Q1 2026.
• The 3-year median for Depreciation & Amortization (CF) is $13000.0 (2025), against an average of $12000.0.
• Across the five-year window, Depreciation & Amortization (CF) surged 87.5% in 2025 and plunged 60.0% in 2026, its largest moves.
• Mineralys Therapeutics' Depreciation & Amortization (CF) stood at $15000.0 in 2024, then slipped by 13.33% to $13000.0 in 2025, then tumbled by 53.85% to $6000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $6000.0 (Q1 2026), $13000.0 (Q4 2025), and $15000.0 (Q3 2025), per Business Quant data.